## What I Did In this iteration, I attempted to validate and expand our experimental targets (Atg7, LC3B, SREBP-1c) by searching for transcriptomic studies that directly correlate caloric restriction-induced gene expression changes with lifespan extension, with particular attention to sex-specific differences. Unfortunately, I ran into technical issues accessing the specific papers identified in this search—the DOI links weren't readable. However, we're building on a solid foundation of insights accumulated from previous iterations that have already mapped out the key pathways and sex-specific effects. ## Key Findings While this specific search hit technical roadblocks, our cumulative understanding remains robust. Here's what stands out from our broader synthesis: **Critical Pathway Validation:** - Autophagy genes (atg-7, bec-1) aren't just associated with CR longevity—they're *causally required* for dietary restriction to extend lifespan in C. elegans (Autophagy is required for DR longevity; bec-1 and atg-7 essential)[https://doi.org/10.4161/auto.4989][https://doi.org/10.1371/journal.pgen.0040024] - SREBP-1c in adipose tissue is similarly *necessary*: knockout completely abolishes CR's lifespan benefits in mice (SREBP-1c/PGC-1α axis in WAT required for CR longevity)[https://doi.org/10.3390/ijms19113335] **Tissue Specificity Matters:** - Intestinal autophagy specifically drives CR's healthspan and longevity benefits (Intestinal autophagy required for DR-mediated healthspan/longevity)[https://doi.org/10.1371/journal.pgen.1006135]—not just any tissue, but the gut **The Sex Difference Smoking Gun:** - CR "feminizes" the male mouse liver transcriptome, shifting male gene expression toward female-typical patterns in metabolic and stress-response pathways (CR feminizes male liver expression)[https://doi.org/10.1371/journal.pone.0005242] - This suggests males may have more "room" to benefit from autophagy enhancement because their baseline is lower - CR's effects on circadian and metabolic genes show clear sex-dependent patterns (Sex-specific CR effects on circadian/metabolic genes)[https://doi.org/10.1038/s41598-017-09289-9] ## Current Hypothesis **The Big Idea:** Combining intestinal autophagy enhancement (via Atg7/LC3B overexpression) with adipose metabolic remodeling (via SREBP-1c activation) will extend lifespan more than either alone—and *males will benefit disproportionately* compared to females. **Why this matters:** We're essentially testing whether we can recreate CR's longevity benefits by genetically targeting two separate tissue compartments without dietary restriction. The sex-differential prediction is key: since CR shifts male liver expression toward a more "female-like" state with higher stress response and autophagy activity (CR feminizes male liver)[https://doi.org/10.1371/journal.pone.0005242], males starting from a lower autophagy baseline should see greater benefits when we artificially boost intestinal autophagy. We know from independent studies that: 1. Intestinal autophagy is required for DR longevity (Intestinal autophagy required for DR)[https://doi.org/10.1371/journal.pgen.1006135] 2. Adipose SREBP-1c is required for CR longevity (SREBP-1c required for CR longevity)[https://doi.org/10.3390/ijms19113335] 3. Males show more dramatic transcriptomic shifts under CR (CR feminizes male liver)[https://doi.org/10.1371/journal.pone.0005242] But no one has tested whether combining these tissue-specific interventions produces *synergistic* effects and whether that synergy differs by sex. **The Experimental Approach:** Use male and female mice with intestine-specific (villin-Cre) inducible Atg7 or LC3B overexpression, combined with adipose-specific (adiponectin-Cre) SREBP-1c activation. Four groups per sex: control, intestinal autophagy alone, adipose SREBP-1c alone, and both together. Track lifespan as primary endpoint, with secondary measures including healthspan metrics, autophagic flux, mitochondrial function, and liver transcriptome profiling to see if we're recapitulating the CR "feminization" signature in males. ## Current Objective & Next Steps **Current Objective:** Before committing to this experimental design, I want to identify publicly available datasets that could help validate our gene targets and potentially refine the sex-specific predictions. Specifically, I'm looking for mouse CR studies with both lifespan outcomes and tissue-specific transcriptomics (liver, adipose, intestine) from both sexes. Here's my plan for the next iteration: **Task 1: Find Public Mouse CR Datasets** - Search for publicly available datasets (GEO, ArrayExpress, etc.) from mouse caloric restriction studies - Prioritize datasets that include: - Both male and female data - Multi-tissue transcriptomics (especially liver, adipose, intestine) - Lifespan or aging biomarker data - Longitudinal time points if possible **Why this is valuable:** - We can analyze whether Atg7, LC3B, and SREBP-1c show correlated expression changes with longevity outcomes - We can quantify sex-specific expression patterns to refine our predictions - We might identify additional candidate genes or pathways showing strong sex-differential CR responses - Real data could help us estimate expected effect sizes for power calculations - We can validate the "feminization" phenomenon quantitatively and see which specific genes in our target pathways drive it **Potential outcome:** If I find good datasets, I can provide you with a data-driven refinement of the hypothesis, including specific predictions about fold-change expression levels, potential additional targets, and more precise sex-differential effect size estimates. This would strengthen the experimental proposal considerably. --- **Let me know if you'd like me to proceed with this dataset search, or if you'd prefer I take a different direction! For example, I could instead:** - Move straight to drafting a detailed experimental protocol - Search for existing combinatorial autophagy + metabolic interventions in the literature - Analyze the specific molecular mechanisms linking intestinal autophagy to adipose SREBP-1c (crosstalk pathways) What would be most valuable to you at this stage?